These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29572725)

  • 1. Individual and Institutional Corruption in European and US Healthcare: Overview and Link of Various Corruption Typologies.
    Sommersguter-Reichmann M; Wild C; Stepan A; Reichmann G; Fried A
    Appl Health Econ Health Policy; 2018 Jun; 16(3):289-302. PubMed ID: 29572725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untangling the corruption maze: exploring the complexity of corruption in the health sector.
    Sommersguter-Reichmann M; Reichmann G
    Health Econ Rev; 2024 Jul; 14(1):50. PubMed ID: 38995456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab Biosimilars in the Age of Personalized Medicine.
    Kang J; Pisupati K; Benet A; Ruotolo BT; Schwendeman SP; Schwendeman A
    Trends Biotechnol; 2018 Oct; 36(10):987-992. PubMed ID: 29861288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
    Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.
    Dipasquale V; Romano C
    J Clin Pharm Ther; 2020 Dec; 45(6):1228-1234. PubMed ID: 32743840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring corruption in the South African health sector.
    Rispel LC; de Jager P; Fonn S
    Health Policy Plan; 2016 Mar; 31(2):239-49. PubMed ID: 26104821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches.
    Vian T
    Glob Health Action; 2020; 13(sup1):1694744. PubMed ID: 32194010
    [No Abstract]   [Full Text] [Related]  

  • 12. Why We Must Talk About Institutional Corruption to Understand Wrongdoing in the Health Sector Comment on "We Need to Talk About Corruption in Health Systems".
    Fotaki M
    Int J Health Policy Manag; 2020 May; 9(5):206-208. PubMed ID: 32563221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assays used to assess biosimilarity of therapies for inflammatory bowel disease.
    Veisman I; Ben-Horin S
    Expert Opin Drug Discov; 2020 Feb; 15(2):139-144. PubMed ID: 31805797
    [No Abstract]   [Full Text] [Related]  

  • 14. Corruption in Anglophone West Africa health systems: a systematic review of its different variants and the factors that sustain them.
    Onwujekwe O; Agwu P; Orjiakor C; McKee M; Hutchinson E; Mbachu C; Odii A; Ogbozor P; Obi U; Ichoku H; Balabanova D
    Health Policy Plan; 2019 Sep; 34(7):529-543. PubMed ID: 31377775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions to reduce corruption in the health sector.
    Gaitonde R; Oxman AD; Okebukola PO; Rada G
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008856. PubMed ID: 27528494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary.
    Harsányi A; Csanádi M; Márky K; Vincziczki ÁZ; Kaló Z; Inotai A
    Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):653-659. PubMed ID: 31510811
    [No Abstract]   [Full Text] [Related]  

  • 18. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Clinical Outcomes After Switching from Remicade
    Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
    Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sustainable development goals as a framework to combat health-sector corruption.
    Mackey TK; Vian T; Kohler J
    Bull World Health Organ; 2018 Sep; 96(9):634-643. PubMed ID: 30262945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.